Dyne Therapeutics
DYN
15.97
+0.57
+3.70%
Dyne Therapeutics
US · DYN
#2540 by market cap
Listed 2020
15.97
+0.57
+3.70%
Live - 5344 symbols - heartbeat 67s ago
· 2026-10-08 06:20
Pre-market
15.99
+0.13%
After-hours
16.00
+0.19%
- Market cap
- 2.98B
- P/E (TTM)i
- -4.90
- P/Bi
- 4.25
- EPSi
- -3.47
- Div yieldi
- 0.00%
- 52W posi
- 17%
Reader sentiment
Are you bullish or bearish on DYN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 15.4 percentage points.
Institutional ownership
- Held by institutions
- 100.80% -15.43pp
- Institutions
- 291 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund66.63%
VC/PE Fund17.60%
Hedge Fund12.25%
Public Company3.30%
Government Pension Fund0.61%
Individual/Insider0.27%
Private Company0.18%
Insurance Company0.11%
Top holders as of 2026-06-30
T. Rowe Price Group, Inc.
18.66% · 34.85M sh
BlackRock
6.64% · 12.40M sh
Janus Henderson Group plc
6.42% · 12.00M sh
FMR
6.00% · 11.21M sh
State Street Global Advisors
3.99% · 7.46M sh
Vanguard Capital Management, LLC
3.91% · 7.30M sh
Orbis Investment Management Limited
3.75% · 7.01M sh
TCG Crossover Management, LLC
2.47% · 4.62M sh
Vanguard Portfolio Management, LLC
2.17% · 4.05M sh
Geode Capital Management, LLC
2.00% · 3.74M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 14 buys · 36 sells
| Name | Role | Stake |
|---|---|---|
| John Cox | Chief Executive Officer | 0.10% |
| Catherine Stehman-Breen | Independent Director | 0.05% |
| Oxana Beskrovnaya | Chief Scientific Officer | 0.04% |
| Johanna Friedl-Naderer | Chief Commercial Officer | 0.03% |
| Douglas Kerr | Chief Medical Officer | 0.02% |
| Brian Posner | Director | 0.01% |
| Richard Scalzo | Senior VP and Head of Finance & Administration | 0.01% |
| Erick Lucera | CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer | 0.01% |
| Atlas Venture Advisors, Inc. | -- | -- |
| Edward Hurwitz | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-07 | Douglas Kerr | Chief Medical Officer | Automatic Disposition | -5,035 | $18.88–24.35 |
| 2026-09-07 | Douglas Kerr | Chief Medical Officer | Intent to Sell (Form 144) | -35 | $18.89 |
| 2026-09-07 | John Cox | Chief Executive Officer | Automatic Disposition | -5,658 | $18.88 |
| 2026-09-07 | Johanna Friedl-Naderer | Chief Commercial Officer | Automatic Disposition | -1,085 | $18.88–24.35 |
| 2026-09-03 | Douglas Kerr | Chief Medical Officer | Intent to Sell (Form 144) | -5,000 | $24.35 |
| 2026-08-13 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -2,586,928 | $25.00–26.20 |
| 2026-08-12 | Douglas Kerr | Chief Medical Officer | Automatic Disposition | -1,556 | $26.28 |
| 2026-08-12 | John Cox | Chief Executive Officer | Automatic Disposition | -4,986 | $26.28 |
| 2026-08-12 | Erick Lucera | CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer | Automatic Disposition | -1,797 | $26.28 |
| 2026-08-12 | Johanna Friedl-Naderer | Chief Commercial Officer | Automatic Disposition | -226 | $26.28 |
| 2026-07-26 | Forbion Capital Partners B.V. | -- | Automatic Disposition | -261,460 | $25.50–26.04 |
| 2026-07-06 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -772,451 | $22.79–23.62 |
| 2026-07-06 | Atlas Venture Advisors, Inc. | -- | Open Market Disposition | -5,000 | $23.61 |
| 2026-06-28 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -504,695 | $21.14–21.28 |
| 2026-06-24 | Atlas Venture Advisors, Inc. | -- | Automatic Disposition | -267,760 | $21.02–21.13 |
| 2026-06-24 | Erick Lucera | CFO, Principal Financial Officer & Principal Accounting Officer and Treasurer | Open Market Disposition | -2,362 | $20.37 |
| 2026-06-22 | Forbion Capital Partners B.V. | -- | Automatic Disposition | -263,962 | $20.57–21.47 |
| 2026-06-21 | Barry Greene | Independent Director | Other Derivative Acquisition | +57,463 | $20.87 |
| 2026-06-17 | Forbion Capital Partners B.V. | -- | Automatic Disposition | -84,355 | $20.07–20.14 |
| 2026-06-16 | Forbion Capital Partners B.V. | -- | Intent to Sell (Form 144) | -348,317 | $18.33 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:20:44 · For reference only, not investment advice and not tailored to your situation.